This launch builds on the successful collaboration between Dawn Health and Novartis, following the development of Ekiva MS and Ekiva PNH, and underscores the potential of digital health to transform ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

Though the big game has long been hallowed ground for some of the most entertaining and memorable commercials, they often don ...

Novartis AG (NVS) stock saw a modest uptick, ending the day at $105.48 which represents a slight increase of $0.76 or 0.73% from the prior close of $104.72. The stock opened at $104.47 and touched a ...

Additionally, as the Sandoz spin-off was completed on October 2023, there were no operating results in 2024 related to discontinued operations.

Fox sold out of its inventory of in-game spots by early November, with a 30-second commercial reportedly going for $7 million ...

CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

Deutsche Bank upgraded Novartis (NVS) to Buy from Hold with a price target of CHF 110, up from CHF 100. The firm says the company’s ...

Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...

In this article, we review a number of notable Canadian trademark cases from 2024 and highlight key developments in Canadian ...

Researchers at the Johns Hopkins Kimmel Cancer Center have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune ...